Dermatitis clinical trials at UCLA

1 research study open to eligible people

Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
open to eligible people ages 18-75
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Los Angeles, California and other locations

Last updated: November 13, 2024